Conference Coverage
Conference Coverage
Drug combo improves recurrence-free survival after HCC resection
Study shows significant improvement in recurrence-free survival with atezolizumab and bevacizumab combo.
Conference Coverage
Guidelines for assessing cancer risk may need updating
Whole-exome sequencing reveals cancer risk mutations in patients that would not have qualified for testing based on current guidelines.
Conference Coverage
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
Conference Coverage
‘Exciting’ results for cancer vaccine plus pembro in melanoma
A new randomized study is the first to demonstrate improvement in recurrence-free survival in melanoma with an individualized neoantigen vaccine...
Conference Coverage
Racial disparities in cardiotoxicity after chemotherapy
“The most important message is to look at preexisting cardiovascular disease, oncology diagnosis, and be aware of existing disparities in a...
Conference Coverage
African ancestry genetically linked to worse CRC outcomes
Results from a new study provide greater clarity regarding the genetic piece of the puzzle.
Conference Coverage
Durvalumab pre, post surgery in NSCLC: Practice changing?
A new study’s findings confirm the benefits of neoadjuvant immunotherapy.
Conference Coverage
AI predicts endometrial cancer recurrence
Model uses only digitized histopathology slides, but more validation in other populations is needed.
Conference Coverage
PARP/ATR inhibitor combo shows hints of promise in children with tumors
A phase 1 clinical trial could provide biomarker clues to help guide future studies.
Conference Coverage
Circulating DNA has promise for cancer detection, but faces challenges
Unnecessary procedures and health care challenges could leave Whites as the primary beneficiaries.